Analysts’ Viewpoint on Market Scenario
Strategies adopted by key players are expected to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period.
In September 2020, Eversana Life Science Services, LLC acquired Alkemy Partners, LLC. Alkemy Partners is a consulting firm that provides medical writing, clinical, and market access training solutions for the life sciences industry.
CSOs help achieve brand success and secure financial viability of an emerging pharmaceutical company. CSOs have expertise in various areas such as market analysis, different payer access, and targeting analysis that helps pharmaceutical companies surpass their target goals. This factor is likely to propel the pharmaceutical contract sales outsourcing market in Europe during the forecast period.
Under contract with pharmaceutical or biotech businesses, a contract sales organization (CSO) offers various services and solutions pertaining to pharmaceutical marketing and sales activities.
Deployment of CSOs is a crucial strategic choice in the dynamic pharmaceutical sector. Medical sales outsourcing is critical for the path to commercialization. It offers qualified teams to design and manage specialized projects when the project requires commercial solutions, such as marketing, sales promotion activities, or training.
Sales representatives provide drug information and sales messaging to healthcare professionals through in-person and remote channels. CSO offers complete medical affairs solutions for non-commercial needs, including contract medical science liaisons and medical affairs consulting (MSL).
Increase in R&D and other operating costs in the pharmaceutical industry are inducing medium and large pharmaceutical companies to outsource their sales operations, as it offers cost controls, better results, and flexibility in terms of operations. This is expected to drive the pharmaceutical contract sales outsourcing (CSO) market in Europe during the forecast period.
Increase in presence of prominent players in the region, high investment in research & development for vaccines & biologics, and a surge in the number of pharmaceutical companies are other factors that are likely to drive the market in Europe.
Improved and advanced services provided by the CSOs, such as in the field of non-personal promotions, are expected to drive the pharmaceutical contract sales outsourcing market share in Europe during the forecast period.
Large as well as small pharmaceutical companies are looking for drugs to cost-effectively and rapidly enter their pipelines, and CSOs play an important role in this. Rise in virtual detailing in outsourcing services is increasing dependence on CSO services.
A surge in the usage of tele-detailing drives the non-personal promotion of outsourcing. All these advanced functions including salesforce and customer support are well-established in a CSO, which can help the pharmaceutical brand to get market recognition faster.
Emerging specialty pharma firms have been looking for agreements with established pharmaceutical giants for several years in order to launch their brands.
Large pharmaceutical corporations are eager to collaborate because they need medications that can join their pipelines promptly and economically. Deals exist, ranging from selling commercialization rights entirely to licensing products. Working with a CSO enables young pharmaceutical firms to incorporate flexibility into their sales approach from the start.
Emerging businesses can quickly assemble an agile, scalable, and responsive team to meet customer demands with the help of an experienced CSO partner, thus ensuring that key market segments are serviced by the appropriate sales personnel and scaling up or down as the market demands with no negative effects on internal operations.
In terms of service, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been classified into personal promotion, non-personal promotion, and others.
The personal promotion segment has been split into promotional sales team, key account management, and vacancy management. The non-personal promotion segment has been segregated into tele-detailing, interactive e-detailing, customer service, medical science liaisons, patient engagement services, and others.
The personal promotion segment is projected to boost the Europe pharmaceutical contract sales outsourcing market size from 2022 to 2031. Significant increase in research & development costs, technological advancements, and product innovations in biologics have prompted several pharmaceutical companies to outsource sales services to CSOs. This propels the personal promotion services segment.
Based on therapeutic area, the pharmaceutical contract sales outsourcing (CSO) market in Europe has been divided into cardiovascular disorders, oncology, metabolic disorders, neurology, orthopedic diseases, infectious diseases, and others.
The oncology segment held a major market share in 2021. The segment is likely to expand at a higher CAGR during the forecast period. Increase in the patient population with different types of cancer is expected to drive the segment during the forecast period.
The U.K. accounted for the largest share of around 21% of the market in Europe in 2021. The market in the country is projected to grow at a CAGR of 7.6% from 2022 to 2031.
Well-established healthcare infrastructure, early adoption of technologically advanced services, and an increase in acceptance and demand for pharmaceutical CSO services are the key factors ascribed to the U.K.’s large market share in 2021.
Rest of Europe is anticipated to be the fastest growing region in Europe during the forecast period, owing to a rise in disease burden leading to an increase in infectious diseases testing, and significant costs associated with commercial activities. The market in Italy and Spain is likely to experience moderate growth in the near future due to developments in pharma sales outsourcing.
The pharmaceutical contract sales outsourcing (CSO) industry in Europe is consolidated, with the presence of a small number of leading players. Expansion of product portfolios and mergers & acquisitions are the key strategies adopted by the players.
Leading and prominent players operating in the market in Europe are Ashfield (UDG Healthcare plc), Syneos Health, IQVIA, Inc., GTS Solution, EVERSANA, MaBiCo, Pharmaforce Ireland, Sales Focus, Inc., Amplity Health, PharmaLex GmbH, Star OUTiCO, and NiSiPharm GmbH.
In March 2021, IQVIA collaborated with Janssen Research & Development on phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digital patient engagement strategies.
In February 2021, Ashfield engaged in a partnership with Popit to improve patient adherence. This enabled Ashfield to bring together novel technologies and patient support programs to proactively respond to patients’ needs and tailor their reminders accordingly.
In December 2020, Syneos Health announced the acquisition of Illingworth Research Group. The acquisition adds new scale and capabilities to Syneos Health’s decentralized clinical trial solutions.
In June 2020, PharmaLex GmbH completed the merger with Regulis Consulting Limited (Regulis) in the U.K. to increase its share in the market
In May 2019, Vanguard Pharma expanded its product portfolio to new and exciting parts of the health care business
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 2.2 Bn |
|
Market Forecast Value in 2031 |
More than US$ 4.6 Bn |
|
Growth Rate (CAGR) |
7.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as at regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
Market share analysis by company (2021) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials. |
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Countries/Sub-region Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The market in Europe was valued at US$ 2.2 Bn in 2021
The market in Europe is projected to reach more than US$ 4.6 Bn by 2031
The pharmaceutical contract sales outsourcing (CSO) market in Europe is anticipated to grow at a CAGR of 7.6% from 2022 to 2031
Increase in R&D and other operating costs in the pharmaceutical industry
The personal promotion segment held over 60% share of the market in the region in 2021
The U.K. is expected to account for major share of the market in the region during the forecast period
Ashfield (UDG Healthcare plc), Syneos Health, IQVIA, Inc., GTS Solution, EVERSANA, MaBiCo, Pharmaforce Ireland Ltd., Sales Focus, Inc., Amplity Health, PharmaLex GmbH, Star OUTiCO, and NiSiPharm GmbH
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Europe Healthcare Industry Overview
5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.3. COVID-19 Pandemic Impact on Industry (value chain and short /mid / long term impact)
6. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Service, 2017–2031
6.3.1. Personal Promotion
6.3.1.1. Promotional Sales Team
6.3.1.1.1. Dedicated Sales Team
6.3.1.1.2. Syndicated Sales Team
6.3.1.2. Key Account Management
6.3.1.3. Vacancy Management
6.3.2. Non-personal Promotion
6.3.2.1. Tele-detailing
6.3.2.2. Interactive E-detailing
6.3.2.3. Customer Service
6.3.2.4. Medical Science Liaisons
6.3.2.5. Patient Engagement Services
6.3.2.6. Others
6.3.3. Other Services
6.4. Market Attractiveness Analysis, by Service
7. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2031
7.3.1. Cardiovascular Disorders
7.3.2. Oncology
7.3.3. Metabolic Disorders
7.3.4. Neurology
7.3.5. Orthopedic Diseases
7.3.6. Infectious Diseases
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Market Attractiveness Analysis, by Country/Sub-region
9. Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Service, 2017–2031
9.2.1. Personal Promotion
9.2.1.1. Promotional Sales Team
9.2.1.1.1. Dedicated Sales Team
9.2.1.1.2. Syndicated Sales Team
9.2.1.2. Key Account Management
9.2.1.3. Vacancy Management
9.2.2. Non-personal Promotion
9.2.2.1. Tele-detailing
9.2.2.2. Interactive E-detailing
9.2.2.3. Customer Service
9.2.2.4. Medical Science Liaisons
9.2.2.5. Patient Engagement Services
9.2.2.6. Others
9.2.3. Other Services
9.3. Market Value Forecast, by Therapeutic Area, 2017–2031
9.3.1. Cardiovascular Disorders
9.3.2. Oncology
9.3.3. Metabolic Disorders
9.3.4. Neurology
9.3.5. Orthopedic Diseases
9.3.6. Infectious Diseases
9.3.7. Others
9.4. Market Attractiveness Analysis
9.4.1. By Service
9.4.2. By Therapeutic Area
10. U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Service, 2017–2031
10.2.1. Personal Promotion
10.2.1.1. Promotional Sales Team
10.2.1.1.1. Dedicated Sales Team
10.2.1.1.2. Syndicated Sales Team
10.2.1.2. Key Account Management
10.2.1.3. Vacancy Management
10.2.2. Non-personal Promotion
10.2.2.1. Tele-detailing
10.2.2.2. Interactive E-detailing
10.2.2.3. Customer Service
10.2.2.4. Medical Science Liaisons
10.2.2.5. Patient Engagement Services
10.2.2.6. Others
10.2.3. Other Services
10.3. Market Value Forecast, by Therapeutic Area, 2017–2031
10.3.1. Cardiovascular Disorders
10.3.2. Oncology
10.3.3. Metabolic Disorders
10.3.4. Neurology
10.3.5. Orthopedic Diseases
10.3.6. Infectious Diseases
10.3.7. Others
10.4. Market Attractiveness Analysis
10.4.1. By Service
10.4.2. By Therapeutic Area
11. France Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Service, 2017–2031
11.2.1. Personal Promotion
11.2.1.1. Promotional Sales Team
11.2.1.1.1. Dedicated Sales Team
11.2.1.1.2. Syndicated Sales Team
11.2.1.2. Key Account Management
11.2.1.3. Vacancy Management
11.2.2. Non-personal Promotion
11.2.2.1. Tele-detailing
11.2.2.2. Interactive E-detailing
11.2.2.3. Customer Service
11.2.2.4. Medical Science Liaisons
11.2.2.5. Patient Engagement Services
11.2.2.6. Others
11.2.3. Other Services
11.3. Market Value Forecast, by Therapeutic Area, 2017–2031
11.3.1. Cardiovascular Disorders
11.3.2. Oncology
11.3.3. Metabolic Disorders
11.3.4. Neurology
11.3.5. Orthopedic Diseases
11.3.6. Infectious Diseases
11.3.7. Others
11.4. Market Attractiveness Analysis
11.4.1. By Service
11.4.2. Therapeutic Area
12. Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Service, 2017–2031
12.2.1. Personal Promotion
12.2.1.1. Promotional Sales Team
12.2.1.1.1. Dedicated Sales Team
12.2.1.1.2. Syndicated Sales Team
12.2.1.2. Key Account Management
12.2.1.3. Vacancy Management
12.2.2. Non-personal Promotion
12.2.2.1. Tele-detailing
12.2.2.2. Interactive E-detailing
12.2.2.3. Customer Service
12.2.2.4. Medical Science Liaisons
12.2.2.5. Patient Engagement Services
12.2.2.6. Others
12.2.3. Other Services
12.3. Market Value Forecast, by Therapeutic Area, 2017–2031
12.3.1. Cardiovascular Disorders
12.3.2. Oncology
12.3.3. Metabolic Disorders
12.3.4. Neurology
12.3.5. Orthopedic Diseases
12.3.6. Infectious Diseases
12.3.7. Others
12.4. Market Attractiveness Analysis
12.4.1. By Service
12.4.2. By Therapeutic Area
13. Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Service, 2017–2031
13.2.1. Personal Promotion
13.2.1.1. Promotional Sales Team
13.2.1.1.1. Dedicated Sales Team
13.2.1.1.2. Syndicated Sales Team
13.2.1.2. Key Account Management
13.2.1.3. Vacancy Management
13.2.2. Non-personal Promotion
13.2.2.1. Tele-detailing
13.2.2.2. Interactive E-detailing
13.2.2.3. Customer Service
13.2.2.4. Medical Science Liaisons
13.2.2.5. Patient Engagement Services
13.2.2.6. Others
13.2.3. Other Services
13.3. Market Value Forecast, by Therapeutic Area, 2017–2031
13.3.1. Cardiovascular Disorders
13.3.2. Oncology
13.3.3. Metabolic Disorders
13.3.4. Neurology
13.3.5. Orthopedic Diseases
13.3.6. Infectious Diseases
13.3.7. Others
13.4. Market Attractiveness Analysis
13.4.1. By Service
13.4.2. By Therapeutic Area
14. Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Service, 2017–2031
14.2.1. Personal Promotion
14.2.1.1. Promotional Sales Team
14.2.1.1.1. Dedicated Sales Team
14.2.1.1.2. Syndicated Sales Team
14.2.1.2. Key Account Management
14.2.1.3. Vacancy Management
14.2.2. Non-personal Promotion
14.2.2.1. Tele-detailing
14.2.2.2. Interactive E-detailing
14.2.2.3. Customer Service
14.2.2.4. Medical Science Liaisons
14.2.2.5. Patient Engagement Services
14.2.2.6. Others
14.2.3. Other Services
14.3. Market Value Forecast, by Therapeutic Area, 2017–2031
14.3.1. Cardiovascular Disorders
14.3.2. Oncology
14.3.3. Metabolic Disorders
14.3.4. Neurology
14.3.5. Orthopedic Diseases
14.3.6. Infectious Diseases
14.3.7. Others
14.4. Market Attractiveness Analysis
14.4.1. By Service
14.4.2. By Therapeutic Area
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2021
15.3. Company Profiles
15.3.1. Ashfield (UDG Healthcare plc)
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Syneos Health
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. IQVIA, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. GTS Solution
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. EVERSANA
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. MaBiCo
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pharmaforce Ireland Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Sales Focus, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Amplity Health
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. PharmaLex GmbH
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Star OUTiCO
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Company Financials
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.12. NiSiPharm GmbH
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Company Financials
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis
List of Tables
Table 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 07: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 08: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 09: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 10: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 11: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 12: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 13: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 14: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 15: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 16: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 17: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 18: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 19: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 20: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 21: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 22: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 23: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 24: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 25: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 26: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 27: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 28: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 29: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 30: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 31: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 32: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 33: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 34: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 35: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 36: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
List of Figures
Figure 01: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Service, 2021
Figure 03: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Therapeutic Area, 2021
Figure 04: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Country/Sub-region, 2021
Figure 05: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 06: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 07: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Personal Promotion, 2017–2031
Figure 08: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Non-personal Promotion, 2017–2031
Figure 09: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031
Figure 10: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 11: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area 2022–2031
Figure 12: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017–2031
Figure 13: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Oncology, 2017–2031
Figure 14: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Metabolic Disorders, 2017–2031
Figure 15: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Neurology, 2017–2031
Figure 16: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Orthopedic Diseases, 2017–2031
Figure 17: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Infectious Diseases, 2017–2031
Figure 18: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031
Figure 19: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 20: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 21: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 22: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 23: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 24: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 25: Germany Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Figure 26: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 27: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 28: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 29: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 30: U.K. Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Figure 31: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 33: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 34: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 35: France Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Figure 36: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 38: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 39: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 40: Italy Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Figure 41: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 42: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 43: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 44: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 45: Spain Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Figure 46: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2021 and 2031
Figure 48: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2022–2031
Figure 49: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2021 and 2031
Figure 50: Rest of Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market
